8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Feb 26, 2026·SEC
Kymera Therapeutics, Inc.(KYMR)Earnings, Financials & Key Ratios
KYMR•NASDAQ
Price updated Jun 19, 2026
AboutKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$39M-16.7%
- EBITDA-$341M-34.1%
- Net Income-$311M-39.1%
- EPS (Diluted)-3.69-23.8%
- Gross Margin100%
- EBITDA Margin-870.12%-61.1%
- Operating Margin-891.33%-60.4%
- Net Margin-794.39%-67.0%
- ROE-25.79%+29.1%
KYMR Key Insights
Kymera Therapeutics, Inc. (KYMR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 46.9% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 12.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KYMR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KYMR Price & Volume
Kymera Therapeutics, Inc. (KYMR) stock price & volume — 10-year historical chart
Loading chart...
KYMR Growth Metrics
Kymera Therapeutics, Inc. (KYMR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years2.87%
3 Years-5.75%
TTM-12.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-30.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-15.48%
Return on Capital
10 Years-36.78%
5 Years-30.08%
3 Years-32.32%
Last Year-27.19%
KYMR Recent Earnings
Kymera Therapeutics, Inc. (KYMR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$0.71+20.2%
$0.89
Rev
$34M+315.7%
$8M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.97-23.8%
$0.78
Rev
$3M-80.9%
$15M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.90-26.8%
$0.71
Rev
$3M-80.9%
$14M
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.95-14.5%
$0.83
Rev
$11M-33.0%
$17M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.71vs $0.89+20.2% | $34Mvs $8M+315.7% |
| Q1 2026 | Feb 26, 2026 | $0.97vs $0.78-23.8% | $3Mvs $15M-80.9% |
| Q4 2025 | Nov 4, 2025 | $0.90vs $0.71-26.8% | $3Mvs $14M-80.9% |
| Q3 2025 | Aug 11, 2025 | $0.95vs $0.83-14.5% | $11Mvs $17M-33.0% |
Based on last 12 quarters of dataView full earnings history →
KYMR Peer Comparison
Kymera Therapeutics, Inc. (KYMR) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 PTGX | 7.26B | 112.86 | -55.05 | -89.41% | -6.48% | -17.76% | 0.02 |
Compare KYMR vs Peers
Kymera Therapeutics, Inc. (KYMR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KYMR Income Statement
Kymera Therapeutics, Inc. (KYMR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 2.93M | 34.03M | 72.83M | 46.83M | 78.59M | 47.07M | 39.2M | 51.47M |
Revenue Growth % | - | - | 1059.99% | 114% | -35.71% | 67.84% | -40.11% | -16.72% | -12.6% |
Cost of Goods Sold | 205K | 825K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | 28.12% | - | - | - | - | - | - | - |
Gross Profit | -205K▲ 0% | 2.11M▲ 1128.8% | 34.03M▲ 1513.8% | 72.83M▲ 114.0% | 46.83M▼ 35.7% | 78.59M▲ 67.8% | 47.07M▼ 40.1% | 39.2M▼ 16.7% | 17.1M▲ 0% |
Gross Margin % | - | 71.88% | 100% | 100% | 100% | 100% | 100% | 100% | 33.23% |
Gross Profit Growth % | - | 1128.78% | 1513.75% | 114% | -35.71% | 67.84% | -40.11% | -16.72% | - |
Operating Expenses | 21.45M | 45.14M | 80.34M | 173.36M | 208.08M | 244.12M | 308.71M | 388.6M | 410.59M |
OpEx % of Revenue | - | 1538.48% | 236.05% | 238.03% | 444.37% | 310.62% | 655.82% | 991.33% | - |
Selling, General & Admin | 3.77M | 7.98M | 18.23M | 36.34M | 43.83M | 55.04M | 63.53M | 68.2M | 72.29M |
SG&A % of Revenue | - | 272.02% | 53.57% | 49.9% | 93.61% | 70.03% | 134.97% | 173.98% | - |
Research & Development | 17.68M | 37.16M | 62.1M | 137.02M | 164.25M | 189.08M | 240.25M | 316.6M | 334.51M |
R&D % of Revenue | - | 1266.46% | 182.48% | 188.13% | 350.76% | 240.59% | 510.38% | 807.65% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 4.92M | 3.8M | -1000K |
Operating Income | -21.45M▲ 0% | -42.2M▼ 96.8% | -46.3M▼ 9.7% | -100.53M▼ 117.1% | -161.26M▼ 60.4% | -165.53M▼ 2.7% | -261.63M▼ 58.1% | -349.4M▼ 33.5% | -359.13M▲ 0% |
Operating Margin % | - | -1438.48% | -136.05% | -138.03% | -344.37% | -210.62% | -555.82% | -891.33% | -697.81% |
Operating Income Growth % | - | -96.75% | -9.71% | -117.11% | -60.41% | -2.65% | -58.06% | -33.54% | - |
EBITDA | -21.25M | -41.38M | -44.54M | -98.13M | -158.28M | -161.97M | -254.26M | -341.09M | -352.16M |
EBITDA Margin % | - | -1410.36% | -130.87% | -134.74% | -338.02% | -206.08% | -540.16% | -870.12% | -684.28% |
EBITDA Growth % | - | -94.77% | -7.64% | -120.32% | -61.29% | -2.33% | -56.99% | -34.15% | -30.3% |
D&A (Non-Cash Add-back) | 205K | 825K | 1.76M | 2.4M | 2.98M | 3.56M | 7.37M | 8.31M | 6.96M |
EBIT | -21.45M | -41.2M | -45.48M | -100.04M | -154.63M | -146.77M | -223.61M | -311.37M | -245.87M |
Net Interest Income | 0 | 959K | 711K | 313K | 6.45M | 18.57M | 37.78M | 37.78M | 28.93M |
Interest Income | 0 | 1M | 826K | 488K | 6.62M | 18.76M | 38.03M | 38.03M | 29.11M |
Interest Expense | 16K | 46K | 115K | 175K | 176K | 196K | 249K | 249K | 116K |
Other Income/Expense | -16K | 959K | 711K | 313K | 6.45M | 18.57M | 37.78M | 37.78M | 43.85M |
Pretax Income | -21.47M▲ 0% | -41.25M▼ 92.1% | -45.59M▼ 10.5% | -100.22M▼ 119.8% | -154.81M▼ 54.5% | -146.96M▲ 5.1% | -223.86M▼ 52.3% | -311.62M▼ 39.2% | -315.28M▲ 0% |
Pretax Margin % | - | -1405.79% | -133.96% | -137.6% | -330.6% | -186.99% | -475.57% | -794.96% | -612.6% |
Income Tax | 43.86K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -21.47M▲ 0% | -41.29M▼ 92.4% | -45.59M▼ 10.4% | -100.22M▼ 119.8% | -154.81M▼ 54.5% | -146.96M▲ 5.1% | -223.86M▼ 52.3% | -311.4M▼ 39.1% | -315.05M▲ 0% |
Net Margin % | - | -1407.36% | -133.96% | -137.6% | -330.6% | -186.99% | -475.57% | -794.39% | -612.17% |
Net Income Growth % | - | -92.35% | -10.42% | -119.81% | -54.47% | 5.07% | -52.32% | -39.11% | -30.79% |
Net Income (Continuing) | -21.47M | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M | -311.62M | -315.28M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.48▲ 0% | -0.93▼ 93.8% | -0.99▼ 6.5% | -2.09▼ 111.1% | -2.87▼ 37.3% | -2.52▲ 12.2% | -2.98▼ 18.3% | -3.69▼ 23.8% | -3.23▲ 0% |
EPS Growth % | - | -93.75% | -6.45% | -111.11% | -37.32% | 12.2% | -18.25% | -23.83% | -15.48% |
EPS (Basic) | -0.48 | -0.93 | -0.99 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 | - |
Diluted Shares Outstanding | 44.53M | 44.53M | 44.56M | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M | 97.53M |
Basic Shares Outstanding | 44.53M | 44.53M | 44.56M | 47.99M | 53.93M | 58.37M | 75.04M | 84.39M | 97.53M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
KYMR Balance Sheet
Kymera Therapeutics, Inc. (KYMR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 41.79M | 92.84M | 302.34M | 451.27M | 419.42M | 405.32M | 510.27M | 871.21M | 677.43M |
Cash & Short-Term Investments | 41.26M | 91.96M | 296.2M | 442.42M | 407.17M | 374.88M | 488.74M | 848.28M | 650.93M |
Cash Only | 41.26M | 76.02M | 31M | 47.98M | 68.39M | 109.97M | 120.26M | 357.01M | 144.09M |
Short-Term Investments | 0 | 15.94M | 265.2M | 394.44M | 338.77M | 264.92M | 368.49M | 491.26M | 506.84M |
Accounts Receivable | 148K | 0 | 1.43M | 135K | 2.54M | 18.76M | 947K | 0 | 0 |
Days Sales Outstanding | - | - | 15.37 | 0.68 | 19.78 | 87.14 | 7.34 | - | 70.92 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 9.71M | 11.67M | 20.58M | 22.94M | 26.5M |
Total Non-Current Assets | 2.44M | 23.86M | 184.84M | 154.63M | 183.72M | 170.44M | 467.77M | 871.6M | 991.58M |
Property, Plant & Equipment | 2.24M | 22.08M | 20.69M | 21.31M | 22.24M | 101.08M | 97.86M | 85.53M | 83.35M |
Fixed Asset Turnover | - | 0.13x | 1.65x | 3.42x | 2.11x | 0.78x | 0.48x | 0.46x | 0.59x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 199K | 0 | 162.53M | 125.19M | 152.33M | 61.43M | 362.16M | 776.96M | 1.56B |
Other Non-Current Assets | 0 | 1.77M | 1.62M | 8.14M | 9.15M | 7.93M | 7.74M | 9.11M | 908.23M |
Total Assets | 44.23M▲ 0% | 116.7M▲ 163.8% | 487.18M▲ 317.5% | 605.9M▲ 24.4% | 603.13M▼ 0.5% | 575.76M▼ 4.5% | 978.03M▲ 69.9% | 1.74B▲ 78.2% | 1.67B▲ 0% |
Asset Turnover | - | 0.03x | 0.07x | 0.12x | 0.08x | 0.14x | 0.05x | 0.02x | 0.04x |
Asset Growth % | - | 163.85% | 317.45% | 24.37% | -0.46% | -4.54% | 69.87% | 78.2% | 203.37% |
Total Current Liabilities | 4.69M | 34.57M | 110.62M | 92.54M | 71.34M | 85.69M | 67.77M | 83.21M | 62.64M |
Accounts Payable | 2.06M | 3.28M | 4.37M | 4M | 4.33M | 7.08M | 5.99M | 4.01M | 12.84M |
Days Payables Outstanding | 3.66K | 1.45K | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.76M | 13.73M |
Deferred Revenue (Current) | 2.32M | 23.35M | 92.55M | 61.74M | 35.26M | 37.88M | 13.58M | 22.93M | 86.2M |
Other Current Liabilities | 1.31M | 0 | 106K | 228K | 303K | 23.16M | 35.09M | 24.2M | 36.07M |
Current Ratio | 8.92x | 2.69x | 2.73x | 4.88x | 5.88x | 4.73x | 7.53x | 10.47x | 10.81x |
Quick Ratio | 8.92x | 2.69x | 2.73x | 4.88x | 5.88x | 4.73x | 7.53x | 10.47x | 10.81x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | 70.92 |
Total Non-Current Liabilities | 73.98M | 156.54M | 92.67M | 53.73M | 41.64M | 95.1M | 74.65M | 79.94M | 66.74M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66.74M |
Capital Lease Obligations | 393K | 17.82M | 14.73M | 14.36M | 13.39M | 78.33M | 74.65M | 68.5M | 210.8M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 73.59M | 109.08M | 100K | 66K | 248K | 0 | 0 | 0 | 0 |
Total Liabilities | 78.67M | 191.11M | 203.29M | 146.27M | 112.98M | 180.79M | 142.42M | 163.15M | 129.38M |
Total Debt | 695K | 21.19M | 17.99M | 17.96M | 17.34M | 84.67M | 87.76M | 82.25M | 80.47M |
Net Debt | -40.56M | -54.82M | -13.01M | -30.01M | -51.06M | -25.29M | -32.49M | -274.76M | -63.62M |
Debt / Equity | - | - | 0.06x | 0.04x | 0.04x | 0.21x | 0.11x | 0.05x | 0.05x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.23x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.18x |
Interest Coverage | -1340.69x | -895.65x | -395.46x | -571.67x | -878.59x | -748.81x | -898.03x | -1250.50x | -2119.53x |
Total Equity | -34.44M▲ 0% | -74.41M▼ 116.1% | 283.89M▲ 481.5% | 459.64M▲ 61.9% | 490.15M▲ 6.6% | 394.97M▼ 19.4% | 835.62M▲ 111.6% | 1.58B▲ 89.0% | 1.54B▲ 0% |
Equity Growth % | - | -116.07% | 481.54% | 61.91% | 6.64% | -19.42% | 111.56% | 89.04% | 232.68% |
Book Value per Share | -0.77 | -1.67 | 6.37 | 9.58 | 9.09 | 6.77 | 11.14 | 18.72 | 15.79 |
Total Shareholders' Equity | -34.44M | -74.41M | 283.89M | 459.64M | 490.15M | 394.97M | 835.62M | 1.58B | 1.54B |
Common Stock | 0 | 0 | 4K | 5K | 6K | 6K | 7K | 8K | 8K |
Retained Earnings | -35.21M | -76.46M | -128.76M | -228.98M | -383.79M | -530.75M | -754.61M | -1.07B | -1.14B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 6K | -128K | -660K | -4.95M | -552K | -1.49M | 1.8M | -4.19M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KYMR Cash Flow Statement
Kymera Therapeutics, Inc. (KYMR) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -17.86M | 17.91M | 88.13M | -128.95M | -153.09M | -102.83M | -194.5M | -232.89M | -242.58M |
Operating CF Margin % | - | 610.26% | 258.95% | -177.05% | -326.92% | -130.84% | -413.2% | -594.11% | - |
Operating CF Growth % | - | 200.24% | 392.21% | -246.31% | -18.72% | 32.83% | -89.16% | -19.74% | -13.76% |
Net Income | -21.47M | -41.25M | -45.59M | -100.22M | -154.81M | -146.96M | -223.86M | -311.35M | -315.05M |
Depreciation & Amortization | 205K | 825K | 1.76M | 2.4M | 2.98M | 3.56M | 7.37M | 8.31M | 8.29M |
Stock-Based Compensation | 648K | 1.2M | 5.19M | 24.97M | 35.48M | 43.12M | 55.01M | 59.9M | 61.68M |
Deferred Taxes | 0 | 0 | 1.57M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 443K | 54.34M | 332K | 5.83M | 889K | -11.8M | -9.06M | -5.02M | -43.16M |
Working Capital Changes | 2.31M | 2.79M | 124.87M | -61.92M | -37.62M | 9.25M | -23.97M | 15.27M | 45.62M |
Change in Receivables | -148K | 0 | -577K | 577K | -2.4M | -16.23M | 17.82M | 947K | 20M |
Change in Inventory | 0 | 0 | 6.88M | 8.71M | 2.4M | 0 | 0 | 0 | 0 |
Change in Payables | 824K | 0 | 990K | 54K | 253K | 0 | -307K | -1.97M | 3.2M |
Cash from Investing | -1.36M | -16.49M | -422.59M | -99.83M | 20.52M | 139.89M | -404.08M | -521.06M | -712.52M |
Capital Expenditures | -1.36M | -532K | -9.1M | -1.6M | -2.84M | -34.48M | -12.84M | -1.45M | -1.42M |
CapEx % of Revenue | - | 18.13% | 26.73% | 2.19% | 6.06% | 43.87% | 27.27% | 3.7% | 2.75% |
Acquisitions | 0 | 0 | 413.49M | 5.81M | -20.52M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -15.95M | -413.49M | -5.81M | 20.52M | 174.37M | 13.98M | 8.88M | -228.22M |
Cash from Financing | 52.93M | 34.91M | 289.26M | 250.28M | 153M | 4.19M | 608.85M | 990.71M | 1.01B |
Debt Issued (Net) | -295K | -371K | -554K | -849K | -1.13M | -76K | -1.58M | -1.49M | -1.22M |
Equity Issued (Net) | 53.23M | 0 | 289.65M | 243.11M | 149.82M | 0 | 596.62M | 992.21M | 951.74M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 35.28M | 162K | 8.02M | 4.3M | 4.27M | 13.81M | 0 | 58.7M |
Net Change in Cash | 33.71M▲ 0% | 36.33M▲ 7.8% | -45.2M▼ 224.4% | 21.5M▲ 147.6% | 20.43M▼ 5.0% | 41.25M▲ 101.9% | 10.27M▼ 75.1% | 236.76M▲ 2204.7% | 54.13M▲ 0% |
Free Cash Flow | -19.22M▲ 0% | 17.37M▲ 190.4% | 79.03M▲ 354.9% | -130.54M▼ 265.2% | -155.92M▼ 19.4% | -137.31M▲ 11.9% | -207.34M▼ 51.0% | -234.34M▼ 13.0% | -244M▲ 0% |
FCF Margin % | - | 592.13% | 232.22% | -179.24% | -332.98% | -174.71% | -440.47% | -597.81% | -474.1% |
FCF Growth % | - | 190.39% | 354.92% | -265.17% | -19.44% | 11.94% | -51.01% | -13.02% | -1.68% |
FCF per Share | -0.43 | 0.39 | 1.77 | -2.72 | -2.89 | -2.35 | -2.76 | -2.78 | -2.50 |
FCF Conversion (FCF/Net Income) | 0.83x | -0.43x | -1.93x | 1.29x | 0.99x | 0.70x | 0.87x | 0.75x | 0.77x |
Interest Paid | 0 | 46K | 0 | 0 | 0 | 162K | 0 | 0 | 83K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KYMR Key Ratios
Kymera Therapeutics, Inc. (KYMR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -43.53% | -26.96% | -32.6% | -33.21% | -36.38% | -25.79% | -25.02% |
Return on Invested Capital (ROIC) | - | -49.03% | -21.53% | -27.84% | -30.7% | -33.46% | -24.86% | -24.38% |
Gross Margin | 71.88% | 100% | 100% | 100% | 100% | 100% | 100% | 33.23% |
Net Margin | -1407.36% | -133.96% | -137.6% | -330.6% | -186.99% | -475.57% | -794.39% | -612.17% |
Debt / Equity | - | 0.06x | 0.04x | 0.04x | 0.21x | 0.11x | 0.05x | 0.05x |
Interest Coverage | -895.65x | -395.46x | -571.67x | -878.59x | -748.81x | -898.03x | -1250.50x | -2119.53x |
FCF Conversion | -0.43x | -1.93x | 1.29x | 0.99x | 0.70x | 0.87x | 0.75x | 0.77x |
Revenue Growth | - | 1059.99% | 114% | -35.71% | 67.84% | -40.11% | -16.72% | -12.6% |
Related:KYMR Dividend History·KYMR Revenue History·KYMR Price History·KYMR P/E History·KYMR Financial Ratios·KYMR Institutional Holders
KYMR SEC Filings & Documents
Kymera Therapeutics, Inc. (KYMR) SEC filings — annual & quarterly reports (10-K, 10-Q)
KYMR Frequently Asked Questions
Kymera Therapeutics, Inc. (KYMR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Kymera Therapeutics, Inc. (KYMR) reported $51.5M in revenue for fiscal year 2025.
Kymera Therapeutics, Inc. (KYMR) saw revenue decline by 16.7% over the past year.
Kymera Therapeutics, Inc. (KYMR) reported a net loss of $315.1M for fiscal year 2025.
Dividend & Returns
Kymera Therapeutics, Inc. (KYMR) has a return on equity (ROE) of -25.8%. Negative ROE indicates the company is unprofitable.
Kymera Therapeutics, Inc. (KYMR) had negative free cash flow of $244.0M in fiscal year 2025, likely due to heavy capital investments.